GlassScriptPhysician profile
Kelli D Bremer
NPI 1902894082
$12,596.88
in general payments reported to CMS, 2019-2025
13 companies · $1,434 in 2025
The $1,434 reported for 2025 was more than what 86% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,458 · 2020: $566 · 2021: $605 · 2022: $762 · 2023: $1,391 · 2024: $1,381 · 2025: $1,434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,205.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $6,446.95 | 2019-2020 | |
| Abbvie INC. | $2,541.16 | 2021-2025 | Vraylar |
| Lundbeck LLC | $1,715.11 | 2019-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $632.57 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $464.63 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $231.64 | 2019-2025 | Invega Sustenna, Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $199.54 | 2019-2025 | Trintellix |
| Axsome Therapeutics, INC. | $123.09 | 2022-2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $70.20 | 2022-2024 | Quviviq |
| Neos Therapeutics, LP | $68.83 | 2022-2024 | Adzenys Xr-Odt |
| Azurity Pharmaceuticals, INC. | $60.71 | 2023-2024 | Horizant, Horizant |
| Alkermes, INC. | $28.51 | 2021-2024 | Aristada, Lybalvi |
| Bausch Health US, LLC | $13.94 | 2023 | Wellbutrin, Aplenzin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelli Bremer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.